Exhibit 99.1
Kim C. Drapkin, Chief Financial Officer, EPIX
(781) 761-7602
Jennifer Beugelmans, Pure Communications
(646) 596-7473
EPIX Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results
Company Announces Reduction In Force and Updates Cash Burn Guidance
Conference Call to be Held Today at 11:00 a.m. EDT
LEXINGTON, Mass — March 12, 2009—
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform today reported financial results for the fourth quarter and full year ended December 31, 2008.
“Our key priority is improving the financial health of EPIX,” said Elkan Gamzu, Ph.D., president and chief executive officer of EPIX. “Although 2008 was a challenging year for EPIX and to date, 2009 has been as well, we continued to make progress toward executing our long-term growth strategy focused on utilizing our in silico drug technology platform as the basis to discover and develop novel therapeutics. From a clinical development perspective, during the past year, we successfully initiated Phase 2b trials for PRX-08066 in patients with chronic obstructive pulmonary disease and for PRX-03140 focused on patients with Alzheimer’s disease. In our preclinical programs, we achieved several milestones with our partners GlaxoSmithKline (GSK) and Cystic Fibrosis Foundation Therapeutics (CFFT), which were revenue-generating events and, in the case of CFFT, led to the expansion of our collaboration. In addition, we successfully achieved U.S. Food and Drug Administration (FDA) approval for Vasovist® (gadofosveset trisodium), our novel blood pool magnetic resonance angiography (MRA) agent. This approval positions the company to pursue a potential monetization strategy for Vasovist. We continue to seek to obtain capital and to advance other components of our overall strategy, including moving our Phase 2b program for PRX-03140 forward.”
Reduction In Force
EPIX announced today that it is further reducing its cost structure by reducing its workforce by approximately 50%, effective immediately. The company plans to maintain the narrowed research and development focus it established in late 2008 which includes its lead clinical program, PRX-03140 being developed for the treatment of Alzheimer’s disease, its partnered preclinical programs with GlaxoSmithKline and Cystic Fibrosis Therapeutics and PRX-08066 being developed for


The following information was filed by Epix Pharmaceuticals, Inc. on Thursday, March 12, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Epix Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Epix Pharmaceuticals, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account